{
    "2021-08-19": [
        [
            {
                "time": "",
                "original_text": "癌症筛查是门好生意吗？美因基因拟赴港上市：癌症筛查业务毛利率达80.5%",
                "features": {
                    "keywords": [
                        "癌症筛查",
                        "美因基因",
                        "赴港上市",
                        "毛利率"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "美年健康扶持起家，美因基因是收智商税吗？",
                "features": {
                    "keywords": [
                        "美年健康",
                        "美因基因",
                        "智商税"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}